Nisa Investment Advisors
ARTV

Nisa Investment Advisors’s Artiva Biotherapeutics ARTV Stock Holding History

Nisa Investment Advisors’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-329
Closed -$497 – 3110
2025
Q2 		$497 Buy
329
+165
+101% +$347 ﹤0.01% 2878
2025
Q1 		$492 Buy
164
+121
+281% +$653 ﹤0.01% 2798
2024
Q4 		$433 Buy
+43
New +$516 ﹤0.01% 2858

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nisa Investment Advisors's ARTV Position: Q3 2025 in Review

Nisa Investment Advisors sold out of Artiva Biotherapeutics (ARTV) in Q3 2025, closing a stake of 329 shares — an estimated $497 sold.

Nisa Investment Advisors first reported a position in ARTV in Q4 2024 and held it in 3 quarters. The position peaked at $497 in Q2 2025. 40 funds tracked by Wall St. Rank hold ARTV as of Q3 2025.

  • Nisa Investment Advisors reported no remaining Artiva Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Nisa Investment Advisors sold 329 Artiva Biotherapeutics shares in Q3 2025, an estimated $497.
  • Nisa Investment Advisors first reported a position in Artiva Biotherapeutics in Q4 2024 and held it in 3 quarters.
  • Nisa Investment Advisors's Artiva Biotherapeutics position peaked at $497 in Q2 2025.
  • 40 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2025.

Based on Nisa Investment Advisors's 13F filing for Q3 2025, filed 23 Oct 2025.